Despite inquiry, FDA AdCom backs BMS Abecma approval
AdCom voted eight to three in favour of BMS and 2seventy bio’s CAR-T cell therapy, Abecma, in triple-class exposed multiple myeloma patients.
AdCom voted eight to three in favour of BMS and 2seventy bio’s CAR-T cell therapy, Abecma, in triple-class exposed multiple myeloma patients.